| Expression pattern: |
UP |
| Associated gene: |
HRNR, SYVN1, mTORC1, p70S6K, PD-L1 |
| Associated microRNA: |
- |
| Biological function: |
Circ-CDYL attenuates the anti-PD-L1 immunotherapy response, promotes HCC cell stemness characteristics, increases malignant cell proliferation, colony formation and tumor spheroid growth, induces PD-L1+ exosomes, inhibits CD8+ T cell proliferation and cytotoxicity, and enhances immune evasion. |
| Molecular mechanism: |
Circ-CDYL binds HRNR protein and stabilizes HRNR by preventing SYVN1-mediated ubiquitination and proteasomal degradation, thereby activating the mTORC1-p70S6K pathway, increasing PD-L1 expression and PD-L1+ exosome production, and promoting immunotherapy resistance and stemness. |
| Biological pathway or process: |
PI3K/AKT/mTOR (promotes); stemness (promotes); proliferation (promotes); apoptosis (inhibits); immune regulation (other); drug resistance (promotes); ubiquitination (inhibits); other pathway/process (promotes) |
| Detected method: |
Q
H
|
| Validation methods: |
RT-qPCR; ISH (In Situ Hybridization); FISH / smFISH; IF (Immunofluorescence); Clinical Sample Validation; RIP (RNA Immunoprecipitation); CLIP; RNA Pull-Down; Co-IP; Transfection; CCK8; Colony Formation Assay; TUNEL; Flow Cytometry（Non-apoptosis/cycle）; In Vivo Animal Model; IHC (Immunohistochemistry); Western Blot; Bioinformatics Analysis |
| Clinical significance: |
Circ-CDYL may serve as a potential biomarker for predicting anti-PD-L1 therapy efficacy in patients with HCC; double-high expression of Circ-CDYL and HRNR was associated with adverse clinicopathological characteristics. |
| Description: |
Circ-CDYL is an oncogenic circRNA studied in HCC that promotes stemness and resistance to anti-PD-L1 immunotherapy. It binds HRNR, blocks SYVN1-mediated HRNR ubiquitination, stabilizes HRNR protein, activates mTORC1-p70S6K signaling, and increases PD-L1 expression and PD-L1+ exosome production, thereby suppressing CD8+ T cell activity and immune killing. |
| Confidence score: |
0.8109 |